A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma
This study aims to evaluate the safety, PK and preliminary anti-tumour activity of SHR-A1912 combined with other therapies in patients with B-cell non-Hodgkin 's lymphoma.
B-cell Non-Hodgkin's Lymphoma
DRUG: SHR-A1912; R-Chemo|DRUG: SHR-A1912; R-Chemo
Phase 1b: RP2D (Recommended Phase II Dose) of SHR-A1912 combined with immunochemotherapy, The RP2D for Phase 2 will be selected at the end of Phase 1b, approximately 12 months|Phase 1b: Incidence and severity of AE, Up to follow-up period, approximately 24 months]|Phase 2: Objective response rate, assessed up to approximately 24 months
Phase 1b: Objective response rate, assessed up to approximately 24 months|Phase 1b: Complete response rate (CRR), assessed up to approximately 24 months|Phase 1b: Duration of remission (DoR), assessed up to approximately 24 months|Phase 1b: Progression-free survival (PFS), assessed up to approximately 24 months|Phase 1b: Toxin binding antibody to SHR-A1912, Up to follow-up period, approximately 24 months|Phase 1b: Total antibody to SHR-A1912, Up to follow-up period, approximately 24 months|Phase 1b: Concentration of free toxin, Up to follow-up period, approximately 24 months|Phase 1b: Anti-drug antibodies (ADA) to SHR-A1912, Up to follow-up period, approximately 24 months|Phase 2: Complete response rate (CRR), assessed up to approximately 24 months|Phase 2: Duration of remission (DoR), assessed up to approximately 24 months|Phase 2: Progression-free survival (PFS), assessed up to approximately 24 months|Phase 2: Incidence and severity of AE, Up to follow-up period, approximately 24 months|Phase 2: Toxin binding antibody to SHR-A1912, Up to follow-up period, approximately 24 months|Phase 2: Total antibody to SHR-A1912, Up to follow-up period, approximately 24 months|Phase 2: Concentration of free toxin, Up to follow-up period, approximately 24 months|Phase 2: Anti-drug antibodies (ADA) to SHR-A1912, Up to follow-up period, approximately 24 months
This study aims to evaluate the safety, PK and preliminary anti-tumour activity of SHR-A1912 combined with other therapies in patients with B-cell non-Hodgkin 's lymphoma.